Ozempic Gastroparesis Settlement: Understanding the Criteria for Eligibility

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Safety Concerns

For decades, general health and science information has served as the foundation for public understanding of wellness, disease prevention, and medical advancements. This broad domain encompasses everything from nutritional guidelines to chronic disease management, providing a baseline of knowledge that empowers individuals to make informed decisions about their health. Within this legacy context, discussions of medication safety and side effects have always been framed in general terms, focusing on population-level risks and benefits without delving into specific mechanisms or individual exposures. As the landscape of pharmaceutical treatments evolves, a more targeted focus has emerged regarding certain widely prescribed medications. One such area of growing attention involves the intersection of diabetes and weight management therapies with gastrointestinal health. Specifically, the medication Ozempic has been linked to reports of gastroparesis—a condition characterized by delayed gastric emptying—in some patients. This has prompted a shift from general health discourse to a more concentrated examination of exposure-related concerns.

Bridging to Ozempic and Gastroparesis

The transition now requires moving from broad health education to a precise inquiry: understanding the criteria for legal settlements related to Ozempic-induced gastroparesis. This pivot necessitates a careful analysis of patient exposure patterns, without delving into mechanistic claims, to clarify eligibility and procedural standards for those affected. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Its mechanism involves slowing gastric emptying, which can contribute to gastrointestinal adverse effects.

Clinical Evidence of Gastrointestinal Adverse Effects

Gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction, presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy or breath tests. The pharmacological action of Ozempic, which delays gastric emptying to promote satiety and improve glycemic control, may exacerbate or induce gastroparesis-like symptoms in susceptible individuals. Evidence from clinical trials indicates that gastrointestinal adverse reactions occur more frequently among patients receiving Ozempic compared to placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients: 3.1% for 0.5 mg and 3.8% for 1 mg, compared to 0.4% for placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with 2 mg (34.0%) versus 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these data do not specifically list gastroparesis, the spectrum of reported symptoms overlaps significantly with gastroparesis presentation.

Mechanistic Pathways and Risk Context

Mechanistic pathways linking Ozempic to gastroparesis involve GLP-1 receptor agonist-induced delay in gastric emptying. This effect is dose-dependent and can persist with chronic use, potentially leading to symptomatic gastroparesis in patients with underlying susceptibility or prolonged exposure. The timeline between exposure and documented harm is variable; symptoms often emerge during dose escalation, as noted in clinical trials where most gastrointestinal reactions occurred during this period (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, delayed onset after months of therapy is also possible, complicating attribution. Regarding risk anchors, the adequacy of warnings about Ozempic and gastroparesis is a critical consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not explicitly mention gastroparesis as a specific adverse effect. The label notes that Ozempic has not been studied in patients with a history of pancreatitis and advises consideration of other therapies in such patients (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, there is no specific warning about gastroparesis risk, which may affect informed consent and patient monitoring.

Settlement Criteria and Eligibility Considerations

For affected patients, settlement-related considerations hinge on demonstrating a causal link between Ozempic use and the development of gastroparesis, supported by temporal association, exclusion of other causes, and clinical documentation. The timeline between exposure and documented harm is crucial; patients who developed symptoms during dose escalation or after prolonged use may have stronger claims. Settlement criteria typically require evidence of a diagnosed gastroparesis, medical records showing Ozempic prescription and use, and a plausible timeline linking the drug to symptom onset. In summary, while Ozempic is effective for glycemic control and cardiovascular risk reduction, its gastrointestinal adverse effects, including potential gastroparesis, warrant careful patient selection and monitoring. The adequacy of current warnings may be insufficient for patients to recognize gastroparesis risk, and affected individuals should seek legal counsel to evaluate settlement options based on individual exposure and harm documentation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) works by slowing gastric emptying, which can lead to gastrointestinal symptoms. In some patients, this effect may exacerbate or induce gastroparesis, a condition of delayed gastric emptying. Clinical trials show higher rates of gastrointestinal adverse reactions in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the settlement criteria for Ozempic-induced gastroparesis?

Settlement criteria typically require documented evidence of a gastroparesis diagnosis, medical records confirming Ozempic prescription and use, and a plausible timeline linking the drug to symptom onset. Patients who developed symptoms during dose escalation or after prolonged use may have stronger claims.

Does Ozempic's prescribing information warn about gastroparesis?

The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not explicitly mention gastroparesis as a specific adverse effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This lack of specific warning may affect informed consent and patient monitoring.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.